Throughout our heritage, we have continued our commitment to innovation, with a focus for the past 7 years on developing our own product candidates in neurology and psychiatry.
| Product | Indication | Status |
| Oxtellar XRTM | Epilepsy | Launched |
| Trokendi XRTM | Epilepsy | Tentative FDA Approval |
| SPN-810 | Impulsive Aggression in ADHD | Completed Phase IIb |
| SPN-812 | ADHD | Completed Phase IIa |
| SPN-809 | Depression | IND filed |
NDA=New Drug Application; IND=Investigational New Drug (application). ADHD=attention-deficit hyperactivity disorder;